Fosun expands drug access: analysts lift target for Fosun International stock to HKD 6.60

Published on 10/25/2026 at 02:47 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Fosun supplied 460 million vials by June 30, 2026. In September 2026, the target for Fosun International stock rose to HKD 6.60 from HKD 5.10.

Healthcare expansion and valuation

Fosun supplied 460 million vials by June 30, 2026.
First-half 2026 revenue reached RMB 86.96 billion and net income RMB 1.72 billion.
Analysts lifted the target from HKD 5.10 to HKD 6.60 in September 2026.
Market capitalization stood at HKD 37.5 billion on October 23, 2026.

Fosun Intl, HK0656038673, Illustration mit AI erstellt.

Fosun International (ISIN HK0656038673) supplied more than 460 million artesunate vials worldwide by June 30, 2026, while analysts lifted their target from HKD 5.10 to HKD 6.60 in September. The latest company message, delivered at a conference on October 20 and published by PR Newswire on October 21, keeps healthcare and international drug access at the center of the investment story.

Healthcare is the latest growth test

Fosun Co-CEO Chen Qiyu said the group is pursuing wider global distribution of Chinese innovative medicines. The release said HANQUYOU, a trastuzumab biosimilar, is available in more than 50 countries and regions, giving the strategy a concrete commercial footprint.

The pharmaceutical focus also carries measurable investment intensity. In the first half of 2026, Fosun Pharma increased total research and development spending 25.66 percent year over year to RMB 3.247 billion, including RMB 2.650 billion for innovative drug research and development, according to PR Newswire.

What did the recent milestones change?

Simply Wall St reported that first-half 2026 revenue reached RMB 86.96 billion, broadly flat year over year, while net income rose 160 percent to RMB 1.72 billion. The profit recovery is substantial, but the group still faces execution risk from research spending, overseas launches and its debt position.

Three dates frame the story

On August 28, 2026, Fosun reported first-half revenue of RMB 86.96 billion and net income of RMB 1.72 billion through Simply Wall St.

On September 24, 2026, Liu Yu joined the board as a non-executive director at age 44, according to Simply Wall St.

On October 21, 2026, Fosun highlighted 460 million supplied artesunate vials and a global rollout for Chinese innovative drugs in its conference release.

Valuation remains the counterweight

Analyst target changes point to a more constructive view of deleveraging and asset recycling. The HKD 6.60 target is 27.78 percent above the HKD 5.16 reference price used in the September assessment, while Simply Wall St also identified debt coverage as a risk.

Stock context in Hong Kong

The last available FOSUF OTC quote stood at USD 0.39 on October 23, 2026 at 4:00 p.m. ET. Fosun International's Hong Kong-listed shares had a HKD 3.42 to HKD 5.67 52-week range in the October 23 market context, with a market capitalization of HKD 37.5 billion.

The last available euro quote from Lang & Schwarz was dated October 24, 2026 and does not establish a trading price for October 25. The further course of trading is shown by the continuously updated real-time quote of Fosun Intl stock.